News Releases

News Releases
Events
Presentations

Year

June 25, 2020

Bioventus Receives FDA Clearance of Strip Format of its SIGNAFUSE Bioactive Bone Graft

DURHAM, NC – June 25, 2020 – Bioventus , a global leader in orthobiologic solutions, is launching its SIGNAFUSE Bioactive Bone Graft in a new strip format. The strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other

June 15, 2020

Bioventus Selects Bazis NN as Distributor of DUROLANE in Russia

HOOFDDORP, THE NETHERLANDS – June 15, 2020 – Bioventus , a global leader in orthobiologic solutions, has selected Bazis NN as its authorized distributor for DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment. OA involves the breakdown, or degeneration, of cartilage and the

March 25, 2020

Bioventus Announces Change in Chief Executive Officer, Ken Reali Appointed to Succeed Tony Bihl Who Will Retire

DURHAM, NC – March 25, 2020 – Tony Bihl , CEO of Bioventus , a global leader in orthobiologic solutions, is electing to retire on April 30, 2020. As a result, the Bioventus Board of Managers has unanimously appointed Ken Reali, former President and CEO of Clinical Innovations, LLC, to assume the

February 24, 2020

Bioventus Recognizes 25 Years of Bone Healing from Exogen

DURHAM, NC – February 24, 2020 – Bioventus , a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System . EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and

February 10, 2020

Bioventus Updates US Label for EXOGEN Ultrasound Bone Healing System

DURHAM, NC – February 10, 2020 – Bioventus , a global leader in orthobiologic solutions, has updated the indications for use for its EXOGEN Ultrasound Bone Healing System . EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and promote

December 18, 2019

Bioventus to Provide Blue Cross Blue Shield of Michigan with Preferred Options for Knee Osteoarthritis Patients, Products include DUROLANE®, GELSYN-3® and SUPARTZ FX®

DURHAM, NC – December 18, 2019 – Beginning January 1, 2020 Bioventus , a global leader in orthobiologic solutions, has secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE , GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis (OA)

October 10, 2019

Bioventus Launches OAKneePainRelief.com

DURHAM, NC – October 10, 2019 – In support of World Arthritis Day, which is celebrated every October 12 to raise awareness of arthritis, Bioventus , a global leader in orthobiologics, has launched a disease and product information website called OAKneePainRelief.com which combines information on

October 8, 2019

National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System

HOOFDDORP, THE NETHERLANDS – October 8, 2019 – Bioventus , a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG12) regarding the use of the EXOGEN Ultrasound Bone

September 9, 2019

Bioventus Agrees to Nationwide Contract with UnitedHealthcare® Commercial Plans, Members Have Access to DUROLANE® and GELSYN-3®for Knee Osteoarthritis

DURHAM, NC – September 9, 2019 – Bioventus , a global leader in orthobiologic solutions, has agreed to a nationwide contract with UnitedHealthcare Employer & Individual commercial plans. Beginning October 1, 2019, UnitedHealthcare commercial plan members will have access to both DUROLANE and

August 13, 2019

Bioventus Launches DUROLANE® SJ (1mL) in Australia and New Zealand; Receives Expanded Indications for DUROLANE (3mL)

HOOFDDORP, THE NETHERLANDS – August 13, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL) , and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand.

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Next page
Last page

Displaying 61 - 70 of 82